


the Claims of Group II in the grandparent case. In the parent case (a divisional of the grandparent case), Applicant elected the Claims of Group I.

Applicant now files another divisional application to prosecute the Claims of Group III (Claims 21-24).

Dated: August 9, 2001



Jason R. Bond
Registration No. 45,439

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
(608) 218-6900

11/11/01 11:11:11 AM

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In The Specification:

Title beginning at line 1, page 1, has been amended as follows:

[Vaccines for Treatment of Lymphoma and Leukemia] Methods of Treating Lymphoma and Leukemia

On page 1, between lines 1 and 2, the following text is inserted:

The present Application is a Divisional of pending U.S. Patent Application Serial No. 09/370,453, filed August 9, 1999, which is a Divisional of U.S. Patent Application Serial No. 08/761,277, filed December 6, 1996, now U.S. Patent 5,972,334, which is a Continuation-in-part of U.S. Patent Application Serial No. 08/644,664, filed May 1, 1996, now U.S. Patent 5,776,746.

In the Claims:

Claims 1-20 have been cancelled.

Claims 21, 22 and 24 have been amended as follows:

21. (amended) A method of treating B-cell lymphoma, comprising:
- a) providing:
 - i) a subject having a B-cell lymphoma; and
 - ii) a multivalent vaccine comprising at least two recombinant heavy chain variable regions of immunoglobulin molecules derived from said subjects's B-cell lymphoma cells, wherein said at least two recombinant heavy chain variable regions differ [cells express at least two different immunoglobulin molecules, said immunoglobulin molecules differing] by at least one idiotope; and
 - b) administering said multivalent vaccine to said subject.

22. (amended) The method of Claim 21, wherein said vaccine comprises at least two recombinant immunoglobulin molecules comprising said recombinant heavy chain variable regions derived from said lymphoma cells.

24. (amended) The method of Claim [22]23, wherein said adjuvant is Syntex adjuvant.

[illegible]

COMPLETE SET OF PENDING CLAIMS

102

21. A method of treating B-cell lymphoma, comprising:

a) providing:

i) a subject having a B-cell lymphoma; and

ii) a multivalent vaccine comprising at least two recombinant heavy chain variable regions of immunoglobulin molecules derived from said subjects's B-cell lymphoma cells, wherein said at least two recombinant heavy chain variable regions differ by at least one idiotope; and

b) administering said multivalent vaccine to said subject.

102

22. The method of Claim 21, wherein said vaccine comprises at least two recombinant immunoglobulin molecules comprising said recombinant heavy chain variable regions derived from said lymphoma cells.

103

23. The method of Claim 21, wherein said vaccine further comprises an adjuvant.

103

24. The method of Claim 23, wherein said adjuvant is Syntex adjuvant.

103

25. The method of Claim 21, wherein at least one of said at least two recombinant heavy chain variable regions is conjugated to a carrier protein.

103

26. The method of Claim 25, wherein said carrier protein is KLH.

102

27. A method of treating B-cell lymphoma, comprising:

a) providing:

i) a subject having a B-cell lymphoma; and

ii) a multivalent vaccine comprising at least two recombinant light chain variable regions of immunoglobulin molecules derived from said subjects's B-cell lymphoma cells, wherein said at least two recombinant light chain variable regions differ by at least one idiotope; and

b) administering said multivalent vaccine to said subject.

28. The method of Claim 27, wherein said vaccine comprises at least two recombinant immunoglobulin molecules comprising said recombinant light chain variable regions derived from said lymphoma cells.

29. The method of Claim 27, wherein said vaccine further comprises an adjuvant.

30. The method of Claim 28, wherein said adjuvant is Syntex adjuvant.

31. The method of Claim 27, wherein at least one of said at least two recombinant light chain variable regions is conjugated to a carrier protein.

32. The method of Claim 31, wherein said carrier protein is KLH.